Notice Number: NOT-NS-10-006
Key Dates
Release Date: January 29, 2010
Issued by
National Institute of Neurological Disorders and Stroke (NINDS) (http://www.ninds.nih.gov)
Purpose
The National Institute of Neurological Disorders and Stroke (NINDS) intends to issue a Program Announcement with set-aside funds in February/March of 2010 to provide support for R01 research project grant applications directed at the validation of novel molecular targets for disease-modifying therapeutic intervention in Huntington’s disease.
This program announcement for Validation of Novel Therapeutic Targets for Huntington’s Disease (HD), represents a collaborative effort between NINDS and CHDI Foundation, Inc. (CHDI) directed at further characterizing novel molecular targets for HD therapeutic development. CHDI will provide funds to NINDS to extend NINDS’ ability to support awards under this PAS. We anticipate there will be sufficient funds to make 8-9 R01 awards in fiscal year 2011 (assuming average direct costs of $250,000 per year and an average length of four years).
Research proposals responsive to the FOA will have the following characteristics:
- A target(s) with a demonstrated direct causal relationship with HD when manipulated genetically or pharmacologically in an in vitro orinvertebrate model of HD.
- Application of a minimum set of best-practice guidelines for genetic and/or pharmacological manipulation of the target in rodent or other in vivo mammalian models of HD.
This notice is being provided to allow potential applicants sufficient time to develop responsive projects.
APPLICATIONS ARE NOT BEING SOLICITED AT THIS TIME.
Inquiries
Direct inquiries regarding this Notice to:
Margaret Sutherland, Ph.D.
Program Director, Neurodegeneration
National Institutes of Health, NINDS
6001 Executive Blvd.
NSC, Room 2222, MSC 9527
Bethesda, MD 20892-9527
Telephone: 301-496-5680
Fax: 301-480-1080
E-mail: sutherlandm@ninds.nih.gov
and Human Services (HHS)
